IL6 and breast cancer: α‐SMA+ fibroblasts were found to show tumor‐restraining activity in solid cancer showing by α‐SMA+ cells depletion assay in mice.[43] Fascinatingly, an in‐depth scRNA‐seq‐based analysis revealed that an IL6‐releasing α‐SMA+ CAF subset is associated with the gemcitabine resistance in pancreatic cancer.[44] In addition, new studies demonstrated that α‐SMA+ CAFs linked to lymph node metastases[45, 46] and a poorer outcome[47] in breast cancer.